The global pruritus therapeutics market revenue was around US$ 8.1 billion in 2022 and is estimated to reach US$ 11.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 3.6% during the forecast period from 2023 to 2031.
Pruritus therapeutics are medications utilized in the treatment of the pruritus disease. Pruritus is the itching caused to the skin owing to different elements such as allergies, dry skin, and other ailments. A more important underlying cause is typically indicated when pruritus persists for a longer period.
Market Driving Factors
The increasing prevalence of pruritus disease is estimated to drive the market growth. Pruritus is a common symptom associated with several medical conditions, including dermatological disorders (psoriasis and eczema), systemic diseases (kidney and liver diseases), and autoimmune conditions (lupus). As the incidence of these conditions rises, so does the prevalence of pruritus, propelling the demand for therapeutic solutions.
Surging discoveries and product innovations are predicted to create opportunities in the market. This is because global private players surge their investment in the research and development of novel therapies and medications due to the increasing demand for pruritus medicines. In addition, major key players have been driven to develop effective and promising drugs due to the growing pruritus sector and the increasing prevalence of skin illnesses and ailments worldwide.
Lack of understanding of the underlying causes of pruritus is impeding the market growth.
Regional Analysis
North America dominated the market in terms of the largest shares and is estimated to maintain its dominance. This can be majorly attributed to the existence of key players, the surge in government initiatives, the well-developed healthcare infrastructure, and the rise in the prevalence of skin-related health problems in the region. For instance, according to the American Academy of Dermatology, new cases of melanoma were 197,700 in 2022, and invasive cases around 99,780 will be diagnosed in the United States.
Asia-Pacific is estimated to dominate the market in terms of the highest growth rate. This is mainly owing to the surge in R&D investments, rise in awareness of newer therapies, and increase in consumer preferences toward over-the-counter products.
Segmentation Insights
Drug Type Insight
The corticosteroids segment is predicted to dominate the market in terms of revenue. This is primarily due to the corticosteroids are anti-inflammatory drugs and are utilized to offer comfort by decreasing inflammation. A few corticosteroids include dexamethasone, cortisone, prednisolone, and hydrocortisone. In addition, corticosteroids reduce itching, allergic responses, redness, and swelling. They are applied to multiple types of pruritus. Due to their broad range of usages, corticosteroids are common pruritus treatments, which contributes to driving the market.
Disease Type Insight
The atopic dermatitis segment is predicted to dominate the market in terms of revenue. Atopic dermatitis is one of the most typical chronic skin diseases, often starting in early childhood. Skin conditions may be associated with allergic asthma, rhinitis, and food allergies. In addition, certain foods such as eggs, citrus fruits, tomatoes & milk can also cause eczema in youngsters. According to the National Eczema Association, approximately 9.6 million children and about 16.5 million adults in the United States have atopic dermatitis, and one-third have moderate to severe conditions.
The urticaria segment is expected to dominate the market in terms of the growth rate. This is generally due to urticaria a common, severely itchy skin disease that causes itchy, red, raised bumps that are milli-meters to centi-meters in size. They can occur anywhere on the body. As a result, most allergists prescribe antihistamines such as fexofenadine, cetirizine, and loratadine to decrease urticaria symptoms.
Prominent Companies
Segmentation Outline
The global pruritus therapeutics market segmentation focuses on the Drug Type, Disease Type, Distribution Channel, and Region.
By Drug Type
By Disease Type
By Distribution Channel
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL PRURITUS THERAPEUTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: PRURITUS THERAPEUTICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL PRURITUS THERAPEUTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE
5.1 OVERVIEW
5.2 CORTICOSTEROIDS
5.3 ANTIHISTAMINES
5.4 LOCAL ANAESTHETICS
5.5 IMMUNOSUPPRESSANT
5.6 OTHERS
6 GLOBAL PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE
6.1 OVERVIEW
6.2 ATOPIC DERMATITIS
6.3 ALLERGIC CONTACT DERMATITIS
6.4 URTICARIA
6.5 OTHERS
7 GLOBAL PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
7.1 OVERVIEW
7.2 HOSPITAL PHARMACIES
7.3 DRUG STORES & RETAIL PHARMACIES
7.3.1 ROUTE OF ADMINISTRATION
7.3.1.1 ORAL
7.3.1.2 PARENTERAL
7.3.1.3 TOPICAL
7.4 ONLINE PROVIDERS
8 GLOBAL PRURITUS THERAPEUTICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL PRURITUS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 ABBVIE INC.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 CIPLA LTD.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 LEO PHARMA
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 GALDERMA S.A.
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 PFIZER INC
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 AMGEN INC.
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 EVELO BIOSCIENCES
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 MC2 THERAPEUITICS
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 EILLY LILLY AND COMPANY
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 VIATRIS INC.
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 NOVAN INC
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 CARA THERAPEUTICS INC.
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 SANOFI
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 TREVI THERAPEUTICS
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 BAUSCH HEALTH COMPANIES INC.
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 NOVARTIS AG
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.17 REGENERON PHARMACEUTICALS INC
10.17.1 OVERVIEW
10.17.2 FINANCIAL PERFORMANCE
10.17.3 PRODUCT OUTLOOK
10.17.4 KEY DEVELOPMENTS
10.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved